No Detail Found!

Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome

Author(s)
Muhammad Abdul Quddus Department of Gastroenterology, Poonch Medical College, Rawalakot, Pakistan
Arslan Shahzad Department of Gastroenterology, Fazaia Medical College Islamabad, Pakistan
Rukhsana Munawar Department of Pharmacology, Poonch Medical College, Rawalakot, Pakistan
Khawaja Tahir Maqbool Department of Gastroenterology, Poonch Medical College, Rawalakot, Pakistan
Amna Mansoor Department of Ophthalmology Al Shifa Eye trust Rawalpindi,Pakistan
Naveed Gani Department of Psychiatry Islam Medical and Dental College, Sialkot, Pakistan
Sheikh Muhammad Taqqi Anwer Department of Gastroenterology, Poonch Medical College, Rawalakot, Pakistan
Abstract
Objective: To study the response of irritable bowel syndrome patients presenting with diarrhea and abdominal pain to the treatment with rifaximin. Study Design: Observational descriptive study. Place and Duration of Study: Study was carried out from 1st February 2019 to 1st December 2019 at Gastroenterology department of Combined Military Hospital Rawalakot. Materials and Methods: Total of 113 patients were consecutively chosen from the Gastroenterology Outpatient Department, Sheikh Khalifa Bin Zayed Al Nahyan Hospital/ AK Combined Military Hospital Rawalakot. Irritable bowel syndrome, diarrhea was diagnosed using Rome III criteria. All participants received 550?mg Rifaximin in two divided doses for a period of fourteen days and were observed for six weeks. The assessed symptoms were diarrhea and abdominal pain, which were recorded at baseline and then at 6 week follow up. Descriptive statistics were done to look for the response of patients' clinical symptoms to Rifaximin. Results: Mean age of the participants was 26.96 years. Out of 113 subjects, 45% were male (51/113) and 55% (62/113) females. Rifaximin was found to be effective in relieving symptoms in 99(87.6%) cases while it did not relieve symptoms in 14 (12.4%) cases. Only 14(12.4%) patients developed headache as a side effect, while the rest 99(87.6%) tolerated it well. Conclusion: Rifaximin is a useful, effective and a safe drug for the treatment of irritable bowel syndrome patients suffering from diarrhea and abdominal pain.
Publication Details
Page(s) 215-218
DOI DOI not available
Published Journal: Journal of Islamic International Medical College, Volume: 16, Issue: 4, Year: 2021

Request the full text from PASTIC

Keywords
diarrhea, Abdominal pain, Irritable bowel syndrome, Rifaximin
0

Citations

0

Downloads

29

Views